• Most Popular
  • Most Shared

Mylan gets FDA nod for 150 mg strength of generic Adoxa

Fri Jun 8, 2007 3:03pm EDT

Stocks

   

Regulatory News

June 8 (Reuters) - Mylan Laboratories Inc. MYL.N said it received final approval from U.S. regulators for the 150 milligram dose of its generic version of Par Pharmaceutical Cos. Inc.'s (PRX.N) antibiotic, marketed as Adoxa.

The product will be shipped immediately, the company said in a statement.

Mylan previously received approval and is marketing the 50 mg, 75 mg and 100 mg strengths of the tablets, generically known as doxycycline.

(Reporting by Varsha Tickoo in Bangalore)

((Editing by Himani Sarkar; Reuters Messaging: varsha.tickoo.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; )) Keywords: MYLAN FDA/PAR

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS3576
Regulatory News


More from Reuters

Afghan insurgents kill CIA agents, Canadians

KABUL (Reuters) - Insurgents intensified their campaign against military targets and U.S.-led forces in Afghanistan, killing eight U.S. CIA agents at a base and four Canadian servicemen on patrol and a journalist accompanying them.

» More Top News
Floor traders work at the Hong Kong Stocks Exchange, January 16, 2008. REUTERS/Bobby Yip

My way or the highway?

Hong Kong is poised to accept Beijing's accounting standards. That's good. The system, though, is prone to scandal. That's bad.  Full Article 

Global Markets
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary